Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutations

Abstract excerpt

Acute myeloid leukemia (AML) and DNMT3A mutations ( DNMT3A mut ) are considered to carry intermediate risk under the 2022 European LeukemiaNet (ELN-2022) classification in the absence of other co-mutations or cytogenetic abnormalities. However, this group is highly heterogeneous. In this study, the genomic and transcriptomic features influencing outcomes in DNMT3A -mutated AML were examined in a cohort of 884...